
Shares of gene therapy maker Sarepta Therapeutics SRPT.O down 16.7% at $18.29 premarket
A patient enrolled in an early-stage study of one of co's gene therapies has died from acute liver failure, as per a Bloomberg report
U.S. FDA is already probing two earlier deaths due to acute liver failure in non-ambulatory Duchenne muscular dystrophy patients after receiving Sarepta's gene therapy, Elevidys
SRPT did not immediately respond to a Reuters' request for comment
As of last close, stock has slumped 81.9% so far this year